UnitedHealth Group: Barclays keeps Overweight rating, raises PT to $352.

UnitedHealth Group: Barclays keeps Overweight rating, raises PT to $352.

September 02, 2025

Barclays has maintained its overweight rating on UnitedHealth Group Incorporated (NYSE: UNH) while raising its price target to $352, according to a recent research report [1]. The investment bank's positive outlook is driven by the company's strong financial performance and the potential for growth in the healthcare sector.

UnitedHealth Group reported revenues of nearly $112 billion in the second quarter of 2025, marking a 13% increase over the prior year's quarter [1]. The company's diversified healthcare operations, including UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx, have contributed to its robust performance.

Barclays analysts highlighted the company's ability to navigate the complexities of the healthcare industry and its potential for long-term growth. They noted that UnitedHealth Group's strong balance sheet and cash flows position it well to capitalize on future opportunities.

The investment bank's decision to raise the price target to $352 reflects its optimism about UnitedHealth Group's prospects. However, it is important for investors to consider the risks associated with the healthcare sector, including regulatory changes and competitive pressures.

Investors interested in UnitedHealth Group should closely monitor the company's earnings reports and any developments in the healthcare industry. As always, it is recommended to conduct thorough research and consider consulting with a financial advisor before making investment decisions.

References:
[1] https://finance.yahoo.com/news/unitedhealth-group-unh-fell-due-141249352.html